 PLYMOUTH MEETING, Pa., April 27, 2021 PRNewswire -- Harmony Biosciences Holdings, Inc. the Company Nasdaq: HRMY, a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced that data from three analyses of the clinical development program for WAKIX pitolisant, a medication approved for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy, will be presented at the 2021 American Psychiatric Association APA Annual Meeting, to be held virtually May 1-3. 